Slingshot members are tracking this event:
AbbVie's Main US Patent on HUMIRA (adalimumab) to expire in December 2016, Still Protected by Dozens of Other Patents
Do you think this event is important to the companies below? How will it affect their stock price?
|Impact on Stocks
Slingshot Insights Explained
Dec 31, 2016
Don’t see a project related to the catalyst you care about?
Related Keywords Patent Expiration, Humira